• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用油酸基脂质纳米粒制剂增强 siRNA 和 microRNA 的肝内递送。

Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.

机构信息

NSF Nanoscale Science and Engineering Center (NSEC), The Ohio State University, Columbus, USA.

出版信息

J Control Release. 2013 Dec 28;172(3):690-8. doi: 10.1016/j.jconrel.2013.09.027. Epub 2013 Oct 8.

DOI:10.1016/j.jconrel.2013.09.027
PMID:24121065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4307782/
Abstract

Many cationic lipids have been developed for lipid-based nanoparticles (LNPs) for delivery of siRNA and microRNA (miRNA). However, less attention has been paid to "helper lipids". Here, we investigated several "helper lipids" and examined their effects on the physicochemical properties such as particle size and zeta potential, as well as cellular uptake and transfection efficiency. We found that inclusion of oleic acid (OA), an unsaturated fatty acid, into the LNP formulation significantly enhanced the delivery efficacy for siRNA and miRNA. For proof-of-concept, miR-122, a liver-specific microRNA associated with many liver diseases, was used as a model agent to demonstrate the hepatic delivery efficacy both in tumor cells and in animals. Compared to Lipofectamine 2000, a commercial transfection agent, LNPs containing OA delivered microRNA-122 in a more efficient manner with a 1.8-fold increase in mature miR-122 expression and a 20% decrease in Bcl-w, a target of microRNA-122. In comparison with Invivofectamine, a commercial transfection agent specifically designed for hepatic delivery, LNPs containing OA showed comparable liver accumulation and in vivo delivery efficiency. These findings demonstrated the importance of "helper lipid" components of the LNP formulation on the cellular uptake and transfection activity of siRNA and miRNA. LNPs containing OA is a promising nanocarrier system for the delivery of RNA-based therapeutics in liver diseases.

摘要

许多阳离子脂质已被开发用于基于脂质的纳米颗粒(LNPs)以递送 siRNA 和 microRNA(miRNA)。然而,人们对“辅助脂质”的关注较少。在这里,我们研究了几种“辅助脂质”,并考察了它们对颗粒大小和 zeta 电位等理化性质以及细胞摄取和转染效率的影响。我们发现,将不饱和脂肪酸油酸(OA)纳入 LNP 配方中显著增强了 siRNA 和 miRNA 的递送效果。为了验证概念,我们选择 miR-122 作为模型药物,miR-122 是一种与许多肝脏疾病相关的肝脏特异性 microRNA,用于在肿瘤细胞和动物中证明其肝脏递送效果。与商业转染试剂 Lipofectamine 2000 相比,含有 OA 的 LNPs 以更高的效率递送 microRNA-122,使成熟的 miR-122 表达增加 1.8 倍,miR-122 的靶标 Bcl-w 减少 20%。与专门用于肝脏递送的商业转染试剂 Invivofectamine 相比,含有 OA 的 LNPs 显示出相当的肝脏积累和体内递送效率。这些发现表明 LNP 配方中“辅助脂质”成分对 siRNA 和 miRNA 的细胞摄取和转染活性的重要性。含有 OA 的 LNPs 是一种有前途的纳米载体系统,可用于肝脏疾病的 RNA 治疗药物的递送。

相似文献

1
Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.利用油酸基脂质纳米粒制剂增强 siRNA 和 microRNA 的肝内递送。
J Control Release. 2013 Dec 28;172(3):690-8. doi: 10.1016/j.jconrel.2013.09.027. Epub 2013 Oct 8.
2
Lipid nanoparticles for hepatic delivery of small interfering RNA.用于小干扰 RNA 肝递送的脂质纳米颗粒。
Biomaterials. 2012 Sep;33(25):5924-34. doi: 10.1016/j.biomaterials.2012.05.002. Epub 2012 May 29.
3
Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.脂质纳米颗粒用于向神经细胞递送 siRNA 的研发。
AAPS J. 2021 Dec 6;24(1):8. doi: 10.1208/s12248-021-00653-2.
4
Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.用于增强 siRNA 和 mRNA 共递送的脂质纳米颗粒制剂。
Nano Lett. 2018 Jun 13;18(6):3814-3822. doi: 10.1021/acs.nanolett.8b01101. Epub 2018 May 8.
5
Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.通过脂质纳米颗粒平台对小干扰RNA肝脏递送的生理和生化屏障进行定量分析。
Mol Pharm. 2014 May 5;11(5):1424-34. doi: 10.1021/mp400584h. Epub 2014 Apr 1.
6
Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.用于优化基于 RNA 的经皮递送至小鼠气道的脂质纳米颗粒制剂。
Eur J Pharm Sci. 2022 Sep 1;176:106234. doi: 10.1016/j.ejps.2022.106234. Epub 2022 Jun 8.
7
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.阳离子脂质纳米粒用于治疗性递送 siRNA 和 miRNA 至小鼠肝肿瘤。
Nanomedicine. 2013 Nov;9(8):1169-80. doi: 10.1016/j.nano.2013.05.007. Epub 2013 May 30.
8
Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver.辅助脂质结构影响蛋白质的吸附和脂质纳米粒向脾和肝的递送。
Biomater Sci. 2021 Feb 21;9(4):1449-1463. doi: 10.1039/d0bm01609h. Epub 2021 Jan 6.
9
Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs.深入了解脂质纳米颗粒的细胞摄取机制和小RNA的细胞内释放。
Pharm Res. 2014 Oct;31(10):2685-95. doi: 10.1007/s11095-014-1366-7. Epub 2014 Apr 17.
10
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.辅助脂质在用于寡核苷酸递送的脂质纳米颗粒(LNP)中的作用。
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):129-137. doi: 10.1016/j.addr.2016.01.022. Epub 2016 Feb 18.

引用本文的文献

1
Design of Clofazimine-Loaded Lipid Nanoparticles Using Smart Pharmaceutical Technology Approaches.运用智能制药技术方法设计载氯法齐明脂质纳米粒
Pharmaceutics. 2025 Jul 2;17(7):873. doi: 10.3390/pharmaceutics17070873.
2
Engineering Nanoparticles and Bioscaffolds for Targeted microRNA Delivery in Cardiovascular Regeneration-A Comprehensive Review.用于心血管再生中靶向递送微小RNA的工程纳米颗粒和生物支架——综述
FASEB J. 2025 Jul 31;39(14):e70871. doi: 10.1096/fj.202501226RR.
3
Vaccine adjuvants for infectious disease in the clinic.临床中用于传染病的疫苗佐剂。

本文引用的文献

1
Size-dependent biodistribution and antitumor efficacy of polymer micelle drug delivery systems.聚合物胶束药物递送系统的尺寸依赖性生物分布及抗肿瘤疗效
J Mater Chem B. 2013 Sep 14;1(34):4273-4280. doi: 10.1039/c3tb20296h. Epub 2013 Jul 15.
2
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.阳离子脂质纳米粒用于治疗性递送 siRNA 和 miRNA 至小鼠肝肿瘤。
Nanomedicine. 2013 Nov;9(8):1169-80. doi: 10.1016/j.nano.2013.05.007. Epub 2013 May 30.
3
Altered mental status in cirrhosis: etiologies and outcomes.
Bioeng Transl Med. 2024 Mar 22;9(4):e10663. doi: 10.1002/btm2.10663. eCollection 2024 Jul.
4
Preparation and Optimization of MiR-375 Nano-Vector Using Two Novel Chitosan-Coated Nano-Structured Lipid Carriers as Gene Therapy for Hepatocellular Carcinoma.使用两种新型壳聚糖包被的纳米结构脂质载体制备并优化miR-375纳米载体用于肝细胞癌的基因治疗
Pharmaceutics. 2024 Apr 3;16(4):494. doi: 10.3390/pharmaceutics16040494.
5
MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?酒精性肝病和肝细胞癌中的微小RNA:迈向新治疗方法的一步?
Cancers (Basel). 2023 Nov 23;15(23):5557. doi: 10.3390/cancers15235557.
6
Nanocarrier-Mediated Delivery of MicroRNAs for Fibrotic Diseases.纳米载体介导的 microRNAs 递送至纤维性疾病。
Mol Diagn Ther. 2024 Jan;28(1):53-67. doi: 10.1007/s40291-023-00681-y. Epub 2023 Oct 28.
7
Development and Characterization of Cationic Nanostructured Lipid Carriers as Drug Delivery Systems for miRNA-27a.阳离子纳米结构脂质载体作为miRNA - 27a药物递送系统的开发与表征
Pharmaceuticals (Basel). 2023 Jul 14;16(7):1007. doi: 10.3390/ph16071007.
8
mRNA therapy for myocardial infarction: A review of targets and delivery vehicles.用于心肌梗死的mRNA疗法:靶点与递送载体综述
Front Bioeng Biotechnol. 2022 Nov 25;10:1037051. doi: 10.3389/fbioe.2022.1037051. eCollection 2022.
9
Conformationally Restricted Dipeptide-Based Nanoparticles for Delivery of siRNA in Experimental Liver Cirrhosis.用于在实验性肝硬化中递送小干扰RNA的构象受限二肽基纳米颗粒
ACS Omega. 2022 Oct 4;7(41):36811-36824. doi: 10.1021/acsomega.2c05292. eCollection 2022 Oct 18.
10
MiRNA as a Potential Target for Multiple Myeloma Therapy-Current Knowledge and Perspectives.微小RNA作为多发性骨髓瘤治疗的潜在靶点——当前认知与展望
J Pers Med. 2022 Aug 31;12(9):1428. doi: 10.3390/jpm12091428.
肝硬化患者精神状态改变:病因和转归。
J Investig Med. 2013 Apr;61(4):695-700. doi: 10.2310/JIM.0b013e318289e254.
4
Liver: Size matters: effects of reduced paracetamol pack sizes in England and Wales.肝脏:剂量很关键:英格兰和威尔士对乙酰氨基酚包装规格减小的影响
Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):197. doi: 10.1038/nrgastro.2013.33. Epub 2013 Feb 26.
5
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.在有肝脏受累的癌症患者中,针对 VEGF 和 KSP 的 RNA 干扰治疗药物的首次人体试验。
Cancer Discov. 2013 Apr;3(4):406-17. doi: 10.1158/2159-8290.CD-12-0429. Epub 2013 Jan 28.
6
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.MicroRNA-122 在肝脏稳态和肝癌发生中发挥着关键作用。
J Clin Invest. 2012 Aug;122(8):2884-97. doi: 10.1172/JCI63455. Epub 2012 Jul 23.
7
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.miR-122 在肝脏中的基本代谢、抗炎和抗肿瘤功能。
J Clin Invest. 2012 Aug;122(8):2871-83. doi: 10.1172/JCI63539. Epub 2012 Jul 23.
8
Lipid nanoparticles for hepatic delivery of small interfering RNA.用于小干扰 RNA 肝递送的脂质纳米颗粒。
Biomaterials. 2012 Sep;33(25):5924-34. doi: 10.1016/j.biomaterials.2012.05.002. Epub 2012 May 29.
9
SPANosomes as delivery vehicles for small interfering RNA (siRNA).SPAN 体作为小干扰 RNA(siRNA)的递药载体。
Mol Pharm. 2012 Feb 6;9(2):201-10. doi: 10.1021/mp200426h. Epub 2011 Dec 29.
10
Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.半乳糖修饰的阳离子脂质体作为小干扰 RNA 的肝靶向递药系统。
Biol Pharm Bull. 2011;34(8):1338-42. doi: 10.1248/bpb.34.1338.